AbbVie Has Long-Term Data from Phase 3 Studies in Rheumatoid Arthritis

– Data from SELECT-EARLY and SELECT-COMPARE show a significantly higher proportion of patients treated with upadacitinib monotherapy or in combination with methotrexate (MTX) maintaining clinical remission compared with MTX or adalimumab plus MTX, respectively, at 48 weeks^1,2

– Findings from an integrated safety analysis across five studies in the SELECT Phase 3 clinical program support the well-characterized safety profile of upadacitinib in patients with moderately to severely active rheumatoid arthritis³

– Upadacitinib, an investigational oral agent engineered by AbbVie to selectively inhibit JAK1, is being studied as a once-daily therapy in moderately to severely active rheumatoid arthritis and across multiple other immune-mediated inflammatory diseases

https://www.prnewswire.com/news-releases/new-long-term-data-from-upadacitinib-phase-3-studies-in-rheumatoid-arthritis-including-results-on-clinical-remission-at-48-weeks-presented-at-eular-300865570.html